Surgical Science Sweden ABSUSRF -2.20%82 3-Year ROIIC % is 68.48 as of Dec. 2025, which is 1562% above its 10-year median of 4.12. GuruFocus rates SUSRF with a GF Score™ of 82/100 and a GF Value™ of $18.98 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 619 Healthcare Providers & Services companies, Surgical Science Sweden AB ranks better than 86.43% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Surgical Science Sweden AB's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 68.48%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Surgical Science Sweden AB's 3-Year ROIIC % or its related term are showing as below:
SUSRF's 3-Year ROIIC % is ranked better than 86.43% of 619
companies
in the Healthcare Providers & Services industry
Industry Median: 3.28
vs SUSRF: 68.48
Surgical Science Sweden AB (OTCPK:SUSRF) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Surgical Science Sweden AB 3-Year ROIIC % Related Terms
Surgical Science Sweden AB 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SUSRF vs VEEV, BTSG, TEM: 3-Year ROIIC % Comparison
For the Health Information Services subindustry, Surgical Science Sweden AB's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Surgical Science Sweden AB 3-Year ROIIC % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Surgical Science Sweden AB's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Surgical Science Sweden AB's 3-Year ROIIC % falls into.
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 4.9460276 (Dec. 2025) - 14.142786 (Dec. 2022) )
/
( 429.228 (Dec. 2025) - 398.558 (Dec. 2022) )
=
-9.1967584
/
30.67
=
-29.99%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Surgical Science Sweden AB (SUSRF) has a 3-Year ROIIC % of 68.48 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Surgical Science Sweden AB and its competitors. This is 1562% above median its historical median of 4.12. According to the industry distribution chart, Surgical Science Sweden AB ranks #84 out of 619 companies in the Healthcare Providers & Services industry, placing it in the top 13.6%.
Is Surgical Science Sweden AB's 3-Year ROIIC % too high?
Surgical Science Sweden AB's current 3-Year ROIIC % of 68.48 is 1562% above median its 10-year median of 4.12. The Healthcare Providers & Services industry median 3-Year ROIIC % is 3.28. Surgical Science Sweden AB's value of 68.48 is 1987.8% above this industry median. Based on the distribution chart, Surgical Science Sweden AB ranks #84 out of 619 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Surgical Science Sweden AB has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Surgical Science Sweden AB's 3-Year ROIIC % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Surgical Science Sweden AB ranks #84 out of 619 companies for 3-Year ROIIC %. This places Surgical Science Sweden AB in the top 14% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 3.28. Surgical Science Sweden AB's value of 68.48 is 1987.8% above this benchmark. While the company's 10-year median is 4.12 vs. the industry median of 3.28, Surgical Science Sweden AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Healthcare Providers & Services company?
The median 3-Year ROIIC % among Healthcare Providers & Services companies is 3.28, based on 619 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Surgical Science Sweden AB's current 3-Year ROIIC % of 68.48 is 1987.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Surgical Science Sweden AB and its competitors. For the Healthcare Providers & Services industry, the median 3-Year ROIIC % is 3.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Surgical Science Sweden AB's current 3-Year ROIIC % is 68.48, which is 1562% above median its own 10-year median of 4.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surgical Science Sweden AB stock overvalued right now?
Based on GuruFocus' analysis, Surgical Science Sweden AB (SUSRF) is currently considered Significantly Undervalued. The stock's GF Value™ is $18.98, compared to a current price of $4.00 — trading 78.9% below its estimated fair value. The current 3-Year ROIIC % is 68.48, which is 1562% above median its 10-year median of 4.12 and 1987.8% above the Healthcare Providers & Services industry median of 3.28. Surgical Science Sweden AB's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Surgical Science Sweden AB (SUSRF), the current 3-Year ROIIC % is 68.48 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Surgical Science Sweden AB (SUSRF) Overvalued in 2026?
Based on GuruFocus' analysis, Surgical Science Sweden AB stock appears to be undervalued.
The current stock price of $4.00 is trading 78.9% below its estimated GF Value™ of $18.98.
GuruFocus considers Surgical Science Sweden AB to be Significantly Undervalued.
Key valuation signals for SUSRF:
3-Year ROIIC %: 68.48 (1562% above median its 10-year median of 4.12)
GF Value™: $18.98 vs. price of $4.00 (78.9% below fair value)
Industry Position: 1987.8% above the Healthcare Providers & Services median (#84 of 619)
No single metric tells the full story. See the SUSRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Surgical Science Sweden AB is a supplier of virtual reality simulators for medical training. The company's core is its proprietary software and hardware for simulating interactions between instruments and anatomy. It has two operating segments: Educational products include Proprietary brand medical simulator hardware and software for generic training of psycho-motor skills, instrument handling, and training for a large number of procedures and examinations prior to entering the clinical environment, as well as support and services. Industry/OEM includes simulation software for product-specific training of surgeons in robot-assisted surgery and other digitalized medical instruments, and also simulators for medical device companies.
82GF Score
Get the complete analysis for SUSRF
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SUSRF has been successfully added to your 
